Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials

INTRODUCTION: Fingolimod has demonstrated clinical and MRI benefits versus placebo/interferon β-1a in young adults with multiple sclerosis (MS). Here we report the long-term effects of fingolimod 0.5 mg on clinical and MRI outcomes in young adults with MS aged ≤ 30 years followed up for up to 8 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghezzi, Angelo, Chitnis, Tanuja, K-Laflamme, Annik, Meinert, Rolf, Häring, Dieter A., Pohl, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858894/
https://www.ncbi.nlm.nih.gov/pubmed/31325110
http://dx.doi.org/10.1007/s40120-019-0146-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858894/
https://www.ncbi.nlm.nih.gov/pubmed/31325110
http://dx.doi.org/10.1007/s40120-019-0146-z

Ejemplares similares